These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 3228706)
21. Structure-activity relationship of anthracycline-induced genotoxicity in vitro. Westendorf J; Marquardt H; Marquardt H Cancer Res; 1984 Dec; 44(12 Pt 1):5599-604. PubMed ID: 6388827 [TBL] [Abstract][Full Text] [Related]
22. Comparative nuclear and cellular incorporation of daunorubicin, doxorubicin, carminomycin, marcellomycin, aclacinomycin A and AD 32 in daunorubicin-sensitive and -resistant Ehrlich ascites in vitro. Seeber S; Loth H; Crooke ST J Cancer Res Clin Oncol; 1980; 98(2):109-18. PubMed ID: 6938517 [TBL] [Abstract][Full Text] [Related]
23. Further examination of 9-alkyl- and sugar-modified anthracyclines in the circumvention of multidrug resistance. Coley HM; Twentyman PR; Workman P Anticancer Drug Des; 1992 Dec; 7(6):471-81. PubMed ID: 1337431 [TBL] [Abstract][Full Text] [Related]
24. Comparative effects of fagaronine, adriamycin and aclacinomycin on K562 cell sensitivity to natural-killer-mediated lysis. Lack of agreement between alteration of transferrin receptor and CD15 antigen expressions and induction of resistance to natural killer. Benoist H; Comoe L; Joly P; Carpentier Y; Desplaces A; Dufer J Cancer Immunol Immunother; 1989; 30(5):289-94. PubMed ID: 2624922 [TBL] [Abstract][Full Text] [Related]
25. Decreased resistance to N,N-dimethylated anthracyclines in multidrug-resistant Friend erythroleukemia cells. Schaefer A; Westendorf J; Lingelbach K; Schmidt CA; Mihalache DL; Reymann A; Marquardt H Cancer Chemother Pharmacol; 1993; 31(4):301-7. PubMed ID: 8422694 [TBL] [Abstract][Full Text] [Related]
26. Effect of anthracycline analogues on the appearance of newly synthesized total RNA and messenger RNA in the cytoplasm of erythroleukemia cells. Long BH; Willis CE; Prestayko AW; Crooke ST Mol Pharmacol; 1982 Jul; 22(1):152-7. PubMed ID: 6956804 [TBL] [Abstract][Full Text] [Related]
27. Transcriptional and posttranscriptional regulation of erythroid gene expression in anthracycline-induced differentiation of human erythroleukemic cells. Morceau F; Chénais B; Gillet R; Jardillier JC; Jeannesson P; Trentesaux C Cell Growth Differ; 1996 Aug; 7(8):1023-9. PubMed ID: 8853898 [TBL] [Abstract][Full Text] [Related]
28. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds. Wadler S; Fuks JZ; Wiernik PH J Clin Pharmacol; 1986; 26(7):491-509. PubMed ID: 2944917 [TBL] [Abstract][Full Text] [Related]
29. Enzymatic and chemical footprinting of anthracycline antitumor antibiotics and related saccharide side chains. Shelton CJ; Harding MM; Prakash AS Biochemistry; 1996 Jun; 35(24):7974-82. PubMed ID: 8672501 [TBL] [Abstract][Full Text] [Related]
30. Experimental studies of new anthracyclines: aclacinomycin, THP-adriamycin and ditrisarubicins. Umezawa K; Kunimoto S; Takeuchi T Biomed Pharmacother; 1987; 41(5):206-13. PubMed ID: 2444279 [TBL] [Abstract][Full Text] [Related]
31. Comparative murine metabolism and disposition of class II anthracycline antibiotics. Dodion P; Egorin MJ; Riggs CE; Ferraro TA; Tamburini JM; Bachur NR Cancer Chemother Pharmacol; 1985; 15(2):153-60. PubMed ID: 3860304 [TBL] [Abstract][Full Text] [Related]
32. Antitumor agents from bohemic acid complex, III. The isolation of marcellomycin, musettamycin, rudolphomycin, mimimycin, collinemycin, alcindoromycin, and bohemamine. Nettleton DE; Balitz DM; Doyle TW; Bradner WT; Johnson DL; O'Herron FA; Schreiber RH; Coon AB; Moseley JE; Myllymaki RW J Nat Prod; 1980; 43(2):242-58. PubMed ID: 7381507 [TBL] [Abstract][Full Text] [Related]
33. Desorption chemical ionization mass spectrometry of anthracyclines and of trisaccharides related to aclacinomycin A and marcellomycin. Monneret C; Sellier N Biomed Environ Mass Spectrom; 1986 Jul; 13(7):319-26. PubMed ID: 2943345 [TBL] [Abstract][Full Text] [Related]
34. Alterations in tyrosine phosphorylation during the granulocytic maturation of HL-60 leukemia cells. Frank DA; Sartorelli AC Cancer Res; 1988 Jan; 48(1):52-8. PubMed ID: 2825968 [TBL] [Abstract][Full Text] [Related]
35. Isolation and characterization of high and low differentiation-inducible Friend leukemia lines. Ikawa Y; Aida M; Inoue Y Gan; 1976 Oct; 67(5):767-70. PubMed ID: 1071084 [TBL] [Abstract][Full Text] [Related]
36. Viscometric and fluorometric studies of deoxyribonucleic acid interactions of several new anthracyclines. Pachter JA; Huang CH; DuVernay VH; Prestayko AW; Crooke ST Biochemistry; 1982 Mar; 21(7):1541-7. PubMed ID: 6952937 [TBL] [Abstract][Full Text] [Related]
37. Increased expression of GATA-1 and NFE-2 erythroid-specific transcription factors during aclacinomycin-mediated differentiation of human erythroleukemic cells. Trentesaux C; Nyoung MN; Aries A; Morceau F; Ronchi A; Ottolenghi S; Jardillier JC; Jeannesson P Leukemia; 1993 Mar; 7(3):452-7. PubMed ID: 8445949 [TBL] [Abstract][Full Text] [Related]
38. The role of two interferon-induced enzymatic activities in erythroid differentiation of Friend cells. Rossi GB; Affabris E; Romeo G; Federico M; Coccia E; Mechti N; Lebleu B Prog Clin Biol Res; 1985; 202():285-96. PubMed ID: 3913962 [No Abstract] [Full Text] [Related]
39. New anthracycline antibiotics. Oki T Jpn J Antibiot; 1977 Dec; 30 Suppl():70-84. PubMed ID: 612711 [TBL] [Abstract][Full Text] [Related]
40. [Role of cell pharmacokinetics in the modulation of modalities in the administration of anthracyclines]. Tapiéro H; Boule D; Trincal G; Fourcade A Pathol Biol (Paris); 1987 Jan; 35(1):20-6. PubMed ID: 3550608 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]